Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine, Nuvaxovid,

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season "With today's approval, we will work with our partner Sanofi to provide access to a protein-based, non-mRNA COVID-19 vaccine for ...

There may soon be another COVID-19 vaccine on the market in the U.S. Novavax announced Monday that it has submitted a request to the Food and Drug Administration for emergency use authorization for its vaccine in adults. Unlike the mRNA vaccines from ...

NEW YORK (WABC) -- The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck told CNN in a phone interview Friday.

The Food and Drug Administration (FDA) signed off Wednesday on an emergency use authorization for the Novavax COVID-19 vaccine for individuals 18 years of age and older. The Novavax vaccine is protein-based. It's made with a more conventional technology ...

Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts of the world including Britain and Europe, and is under review ...

The government-funded COVID-19 vaccination program is from Jan. 1 to Feb. 28 next year to be expanded to cover all residents aged six months or older, the Centers for Disease Control (CDC) said today.

Physician and science communicator Kristen Panthagani talks about why public trust in vaccines has fallen since the COVID-19 pandemic.